PBGENE-PMM
Primary Mitochondrial Myopathy (PMM)
PreclinicalAdvancing towards IND/CTA
Key Facts
Indication
Primary Mitochondrial Myopathy (PMM)
Phase
Preclinical
Status
Advancing towards IND/CTA
Company
About Precision BioSciences
Precision BioSciences is a clinical-stage biotech leveraging its proprietary ARCUS genome editing platform to develop potentially curative in vivo therapies for genetic diseases. The company has advanced two wholly-owned programs into Phase 1/2 trials: PBGENE-HBV for chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy, both supported by key regulatory designations. Its strategy combines advancing these core assets with strategic partnerships to validate and fund the ARCUS platform, positioning it in the competitive but high-potential gene editing landscape.
View full company profile